Eli Lilly and Company and Entos Pharmaceuticals, Inc.’s Research and Collaboration Agreement

Torys LLP acted for Entos Pharmaceuticals. On January 6, 2022, Eli Lilly and Company (NYSE:LLY) acquired exclusive rights to Entos’ Fusogenix nucleic acid delivery technology to research,…

This content is for Standard 1 Year members only.
Login Join Now
Sonia Carcano

Author: Sonia Carcano

This content is for Standard 1 Year members only.
Login Join Now